- Be aware, providers should contact and re-dose patients who previously received the 150mg Evushield dose (see below)
- Be Aware, supply of COVID-19 therapeutics is not currently limited in Whatcom County. While COVID-19 case rates are decreasing in Whatcom County, some patients may benefit from therapeutics. Decision to prescribe should be based on clinical criteria and patient interest.
- Be aware, CDC updated its list of underlying medical conditions associated with higher risk of severe outcomes from COVID-19 to include primary immunodeficiency and physical inactivity. The list is not exhaustive. Do not use it to exclude people from recommended preventive measures, like booster doses or needed therapies.
- See National Institutes of Health (NIH) COVID-19 treatment guidelines for more information.
COVID-19 Therapeutics Availability
- Whatcom County now has a good supply of COVID-19 therapeutics. Department of Health and Human Services (HHS) allocates monoclonal antibodies and oral antivirals to each state and the WA DOH distributes doses to enrolled medical providers and pharmacies. All therapies must be dispensed by prescription.
- Oral antivirals: Numerous pharmacies throughout Whatcom County have a regular supply of Molnupiravir and several sites have Paxlovid.
- See the HHS COVID-19 therapeutics locatorfor locations and availability.
- Oral antivirals must be taken ASAP within 5 days of symptom onset; Rx must include date of symptom onset or “do not take after [date]” to ensure 5-day window.
- Monoclonal antibodies: There are currently no supply constraints for Sotrovimab, the mAb effective for treatment of omicron.
- REGEN-COV and Bamlanivimab/Etesevimab mAbs are no longer allowed under EUA anywhere in the U.S. due to the lack of effectiveness against Omicron.
- Infusion Solutions is accepting referrals for patients in all four NIH Risk Tiers. Please use the Infusion Solutions referral form.
- Bebtelovimab received EAU on 2/11 and will likely become more available.
- For general mAb guidance, see Interim-DOH Guidance on Prioritization for Use of Anti SARS-CoV-2 Monoclonal Antibodies.
- Evusheld: Pre-exposure prophylaxis, primarily for immunocompromised or those who cannot be vaccinated.
- See the HHS COVID-19 therapeutics locator for locations and availability.
- On Feb. 24, Food and Drug Administration (FDA) revised its Evusheld emergency use authorization (EUA) (tixagevimab co-packaged with cilgavimab). When used for COVID-19 pre-exposure prophylaxis, the new initial dose is 300 mg tixagevimab and 300 mg cilgavimab. Recent data shows Evusheld may be less active against some Omicron subvariants. Contact patients who received the previous initial dose (150 mg tixagevimab and 150 mg cilgavimab) and ask them to return for an additional 150 mg tixagevimab and 150 mg cilgavimab.
- See updated Evusheld EUA for more information.
Prescribing Information and Tools
- Therapeutics Decision Aid (2-page algorithm, updated 2/24/22):
- Side-by-Side Overview of Therapies (9-page comparison chart):
- Be aware, CDC updated its list of underlying medical conditions associated with higher risk of severe outcomesfrom COVID-19 to include primary immunodeficiency and physical inactivity. The list is not exhaustive. Do not use it to exclude people from recommended preventive measures, like needed therapies or vaccine boosters.
- DOH therapeutics for providers page.
- HHS COVID-19 therapeutics locator for providers.
- NIH COVID-19 treatment guidelines-“what’s new”.
- To manage COVID-19 therapies, providers must enroll in Healthcare Partner Ordering Portal (HPoP). Email firstname.lastname@example.org for more information or support enrolling. Department of Health and Human Services (HHS) allocates monoclonal antibodies and oral antivirals to each state. DOH distributes doses to enrolled providers. Providers must enroll in Healthcare Partner Ordering Portal (HPoP) to manage COVID-19 therapies. Email email@example.com for support enrolling. Once enrolled, to request a supply of monoclonal antibodies or therapeutics, complete a smart sheet.
COVID-19 at-home antigen tests
- Teach patients how to access, use and interpretat-home antigen test kits.
- Teach patients with mild to moderate illness how to care for themselves at home and when to go to the emergency department.
- Share with patients:
- Urge patients to report positive home tests at: https://redcap.link/whatcomreport
Contacting the Health Department
360-778-6100 Main Call Line – available M-F 8:30am to 4:30pm
360-715-2588 Afterhours Answering Service – available after 4:30pm and weekends
360-778-6150 Communicable Disease Report Line – 24 hours a day 7 days a week
360-778-6103 Confidential Communicable Disease Fax – 24 hours a day 7 days a week
1500 N State Street, Bellingham WA 98225